Trial Profile

Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pexidartinib (Primary)
Indications Acute myeloid leukaemia; CNS cancer; Diffuse intrinsic pontine glioma; Ewing's sarcoma; Glioma; Leukaemia; Nerve sheath neoplasms; Neurofibromatosis 1; Plexiform neurofibroma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions

12 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
12 Sep 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
10 Nov 2022 Planned number of patients changed from 81 to 54.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com